CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice

Atherosclerosis

Volumn 232, Issue 1, 2014, Pages 110-118

  Tardy, Claudine ^a   Goffinet, Marine ^a   Boubekeur, Nadia ^a   Ackermann, Rose ^b   Sy, Gavin ^b   Bluteau, Alice ^a   Cholez, Guy ^a   Keyserling, Constance ^a   Lalwani, Narendra ^b   Paolini, John F ^a   Dasseux, Jean Louis ^a   Barbaras, Ronald ^a   Baron, Rudi ^a  

^a Cerenis Therapeutics SA   (France)

^b Cerenis Therapeutics   (United States)

Author keywords

Atherosclerosis regression; HDL mimetics; High density lipoproteins (HDL); Lipoproteins; Reverse lipid transport

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; APOLIPOPROTEIN A1; CER 001; CHOLESTEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FECES ANALYSIS; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVERSE LIPID TRANSPORT; SINGLE DRUG DOSE; UMBILICAL VEIN ENDOTHELIAL CELL;

ATHEROSCLEROSIS REGRESSION; HDL MIMETICS; HIGH DENSITY LIPOPROTEINS (HDL); LIPOPROTEINS; REVERSE LIPID TRANSPORT;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOMIMETICS; CELL ADHESION; CHO CELLS; CHOLESTEROL; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHOLIPIDS; RECOMBINANT PROTEINS;

EID: 84891614269     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.10.018     Document Type: Article

References (47)

1. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R., Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
2. Badimon J.J., Badimon L., Galvez A., Dische R., Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989, 60:455-461.
3. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. JClin Invest 1990, 85:1234-1241.
4. Ameli S., Hultgardh-Nilsson A., Cercek B., Shah P.K., Forrester J.S., Ageland H., Nilsson J. Recombinant apolipoprotein a-i milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994, 90:1935-1941.
5. Ibanez B., Vilahur G., Cimmino G., Speidl W.S., Pinero A., Choi B.G., Zafar M.U., Santos-Gallego C.G., Krause B., Badimon L., Fuster V., Badimon J.J. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein a-i milano (etc-216) administration: Magnetic resonance imaging study in an experimental model of atherosclerosis. JAm College Cardiol 2008, 51:1104-1109.
6. Podrez E.A. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol physiol 2010, 37:719-725.
7. Tabet F., Rye K.A. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (London, England: 1979) 2009, 116:87-98.
8. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., Vahabzadeh K., Hama S., Hough G., Kamranpour N., Berliner J.A., Lusis A.J., Fogelman A.M. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and hdl. JLipid Res. 2004, 45:993-1007.
9. Duffy D., Rader D.J. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113:1140-1150.
10. Julius U., Fisher S. Nicotinic acid as a lipid-modifying drug - a review. Atheroscler Suppl 2013, 14:7-13.
11. Barter P.J., Rye K.A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Res 2012, 53:1755-1766.
12. Duverger N., Kruth H., Emmanuel F., Caillaud J.M., Viglietta C., Castro G., Tailleux A., Fievet C., Fruchart J.C., Houdebine L.M., Denefle P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein a-i-transgenic rabbits. Circulation 1996, 94:713-717.
13. Soma M.R., Donetti E., Parolini C., Sirtori C.R., Fumagalli R., Franceschini G. Recombinant apolipoprotein a-imilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circul Res 1995, 76:405-411.
14. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Ma Lauer, Sheldon W.S., Grines C.L., Halpern S., Crowe T., Blankenship J.C., Kerensky R. Effect of recombinant apoa-i milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
15. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., Kouz S., Berry C., Basser R., Lavoie M.A., Guertin M.C., Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
16. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., Shear C.L., Revkin J.H., Buhr K.A., Fisher M.R., Tall A.R., Brewer B., Investigators I. Effects of torcetrapib in patients at high risk for coronary events. NEngl J Med 2007, 357:2109-2122.
17. Group A.S., Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., Friedewald W.T., Buse J.B., Gerstein H.C., Probstfield J., Grimm R.H., Ismail-Beigi F., Bigger J.T., Goff D.C., Cushman W.C., Simons-Morton D.G., Byington R.P. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362:1563-1574.
18. Nissen S.E., Tardif J.-C., Nicholls S.J., Revkin J.H., Shear C.L., Duggan W.T., Ruzyllo W., Bachinsky W.B., Lasala G.P., Lasala G.P., Tuzcu E.M. Effect of torcetrapib on the progression of coronary atherosclerosis. The New Eng J Med 2007, 356:1304-1316.
19. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: mesa (multi-ethnic study of atherosclerosis). JAm College of Cardiol 2012, 60:508-516.
20. van der Steeg Wa Holme I., Boekholdt S.M., Larsen M.L., Lindahl C., Stroes E.S.G., Tikkanen M.J., Wareham N.J., Faergeman O., Olsson A.G., Pedersen T.R., Khaw K.-T., Kastelein J.J.P. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein a-i: significance for cardiovascular risk: the ideal and epic-norfolk studies. JAm Coll Cardiol 2008, 51:634-642.
21. Wang X., Collins H.L., Ranalletta M., Fuki I.V., Billheimer J.T., Rothblat G.H., Tall A.R., Rader D.J. Macrophage abca1 and abcg1, but not sr-bi, promote macrophage reverse cholesterol transport invivo. JClin Invest 2007, 117:2216-2224.
22. Usui S., Hara Y., Hosaki S., Okazaki M. Anew on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by hplc. JLipid Res. 2002, 43:805-814.
23. Bligh E.G., Dyer W.J. Arapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
24. Park S.H., Park J.H., Kang J.S., Kang Y.H. Involvement of transcription factors in plasma hdl protection against tnf-alpha-induced vascular cell adhesion molecule-1 expression. The Int J Biochem Cell Biol 2003, 35:168-182.
25. Suc I., Brunet S., Mitchell G., Rivard G.E., Levy E. Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse j774 macrophages: role of scavenger receptors, classes a and b. JCell Sci 2003, 116:89-99.
26. Bortnick A.E.A., Rothblat G.H.G.H., Stoudt G., Hoppe K.L., Royer L.J., Mcneish J., Francone O.L. The correlation of atp-binding cassette 1 mrna levels with cholesterol efflux from various cell lines. JBiol Chem 2000, 275:28634-28640.
27. Cogny A., Atger V., Paul J.L., Soni T., Moatti N. High-density lipoprotein 3 physicochemical modifications induced by interaction with human polymorphonuclear leucocytes affect their ability to remove cholesterol from cells. Biochem J 1996, 314(1):285-292.
28. Ross R. Atherosclerosis - an inflammatory disease. NEngl J Med 1999, 340:115-126.
29. Lewis G.F., Rader D.J. New insights into the regulation of hdl metabolism and reverse cholesterol transport. Circul Res 2005, 96:1221-1232.
30. Kawano M., Miida T., Fielding C.J., Fielding P.E. Quantitation of pre beta-hdl-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry 1993, 32:5025-5028.
31. Sekiya M., Osuga J., Igarashi M., Okazaki H., Ishibashi S. The role of neutral cholesterol ester hydrolysis in macrophage foam cells. JAtheroscler Thromb 2011, 18:359-364.
32. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., French B.C., Ja Phillips, Mucksavage M.L., Wilensky R.L., Mohler E.R., Rothblat G.H., Rader D.J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. NEng J Med 2011, 364:127-135.
33. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of hdl. Circ Res. 2004, 95:764-772.
34. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995, 15:1987-1994.
35. Cockerill G.W. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J 2001, 15:1941-1952.
36. Ashby D.T., Rye K.A., Clay M.A., Vadas M.A., Gamble J.R., Barter P.J. Factors influencing the ability of hdl to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 1998, 18:1450-1455.
37. Cockerill G.W., Huehns T.Y., Weerasinghe A., Stocker C., Lerch P.G., Miller N.E., Haskard D.O. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of e-selectin in an invivo model of acute inflammation. Circulation 2001, 103:108-112.
38. Feig J.E., Parathath S., Rong J.X., Mick S.L., Vengrenyuk Y., Grauer L., Young S.G., Fisher E.A. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011, 123:989-998.
39. Tall A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. JIntern Med 2008, 263:256-273.
40. Glomset J.A. The metabolic role of lecithin: cholesterol acyltransferase: perspectives from pathology. Adv Lipid Res. 1973, 11:1-65.
41. Miettinen T.A., Kesaniemi Y.A. Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989, 49:629-635.
42. Harchaoui K.E., Franssen R., Hovingh G.K., Bisoendial R.J., Stellaard F., Kuipers F., Kastelein J.J.P., Kuivenhoven J.A., Stroes E.S.G., Groen A.K. Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia. Atherosclerosis 2009, 207:614-616.
43. Eriksson M., Carlson L.A., Miettinen T.A., Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipo protein a-i. Potential reverse cholesterol transport in humans. Circulation 1999, 100:594-598.
44. Nanjee M.N., Cooke C.J., Garvin R., Semeria F., Lewis G., Olszewski W.L., Miller N.E. Intravenous apoa-i/lecithin discs increase pre-beta-hdl concentration in tissue fluid and stimulate reverse cholesterol transport in humans. JLipid Res. 2001, 42:1586-1593.
45. Brousseau M.E., Diffenderfer M.R., Millar J.S., Nartsupha C., Asztalos B.F., Welty F.K., Wolfe M.L., Rudling M., Bjorkhem I., Angelin B., Mancuso J.P., Digenio A.G., Rader D.J., Schaefer E.J. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein a-i metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25:1057-1064.
46. Brown M.S., Goldstein J.L. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity. Proc Nat Acad Sci U S A 1974, 71:788-792.
47. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the ldl receptor gene in familial hypercholesterolemia. Hum Mutat 1992, 1:445-466.